CN116457027A - 基于哌嗪的阳离子脂质 - Google Patents

基于哌嗪的阳离子脂质 Download PDF

Info

Publication number
CN116457027A
CN116457027A CN202180075719.XA CN202180075719A CN116457027A CN 116457027 A CN116457027 A CN 116457027A CN 202180075719 A CN202180075719 A CN 202180075719A CN 116457027 A CN116457027 A CN 116457027A
Authority
CN
China
Prior art keywords
compound
optionally substituted
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180075719.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·卡马卡尔
R·达萨里
R·兰迪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translation Bio Co
Original Assignee
Translation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translation Bio Co filed Critical Translation Bio Co
Publication of CN116457027A publication Critical patent/CN116457027A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180075719.XA 2020-09-23 2021-09-23 基于哌嗪的阳离子脂质 Pending CN116457027A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082101P 2020-09-23 2020-09-23
US63/082,101 2020-09-23
PCT/US2021/051763 WO2022066916A1 (en) 2020-09-23 2021-09-23 Piperazine-based cationic lipids

Publications (1)

Publication Number Publication Date
CN116457027A true CN116457027A (zh) 2023-07-18

Family

ID=78414070

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180075719.XA Pending CN116457027A (zh) 2020-09-23 2021-09-23 基于哌嗪的阳离子脂质

Country Status (12)

Country Link
US (1) US20230357166A1 (https=)
EP (1) EP4216933B1 (https=)
JP (1) JP7791182B2 (https=)
KR (1) KR20230074526A (https=)
CN (1) CN116457027A (https=)
AU (1) AU2021349262A1 (https=)
BR (1) BR112023005207A2 (https=)
CA (1) CA3193347A1 (https=)
ES (1) ES2994955T3 (https=)
IL (1) IL301536A (https=)
MX (1) MX2023003344A (https=)
WO (1) WO2022066916A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
BR112023020027A2 (pt) * 2021-04-15 2023-11-14 Translate Bio Inc Lipídeos catiônicos baseados em tampão "good"
WO2023178167A1 (en) * 2022-03-16 2023-09-21 Translate Bio, Inc. Asymmetric piperazine-based cationic lipids
US20250263385A1 (en) 2022-04-13 2025-08-21 Sanofi "Good" buffer-based cationic lipids
US20240150306A1 (en) * 2022-09-27 2024-05-09 Reinvigoron Theratech, Inc. Compounds with cleavable disulfide moieties
EP4637813A1 (en) 2022-12-20 2025-10-29 Sanofi Pasteur Rhinovirus mrna vaccine
CN116082275B (zh) * 2023-03-13 2023-07-14 北京悦康科创医药科技股份有限公司 一种脾脏中高表达的阳离子脂质化合物、包含其的组合物及用途
EP4734960A1 (en) 2023-06-28 2026-05-06 Sanofi Pasteur Inc. Sterol analogs in lipid nanoparticle formulations
US12599560B2 (en) 2023-11-02 2026-04-14 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
CN121219273A (zh) * 2023-11-02 2025-12-26 深圳厚存纳米药业有限公司 脂质和脂质纳米颗粒制剂
US12539279B2 (en) 2023-12-11 2026-02-03 The Governing Council Of The University Of Toronto Supramolecular ionizable lipid molecules with heteroatomic tuning for nucleic acid delivery
WO2025141521A1 (en) 2023-12-29 2025-07-03 Sanofi Lipids having dendritic moieties
WO2025160118A1 (en) * 2024-01-22 2025-07-31 The Trustees Of The University Of Pennsylvania Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents
WO2025255534A1 (en) * 2024-06-07 2025-12-11 Innovac Therapeutics Hk Limited Diol-based novel ionizable lipids and their uses thereof
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026053147A1 (en) 2024-09-05 2026-03-12 Sanofi Pasteur Inc. Helper lipids and lnp compositions comprising same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125281A1 (en) * 2001-08-27 2003-07-03 David Lewis Compositions and processes using siRNA, amphipathic compounds and polycations
US20150376144A1 (en) * 2014-06-24 2015-12-31 Shire Human Genetic Therapies, Inc. Stereochemically enriched compositions for delivery of nucleic acids
CN105813656A (zh) * 2013-10-22 2016-07-27 夏尔人类遗传性治疗公司 用于递送信使rna的脂质制剂
CN107848988A (zh) * 2015-06-19 2018-03-27 麻省理工学院 烯基取代的2,5‑哌嗪二酮和其在组合物中用于向个体或细胞递送药剂的用途
CN110167922A (zh) * 2016-11-08 2019-08-23 特拉维夫大学拉莫特有限公司 用于核酸递送的阳离子脂质及其制备
US20200022921A1 (en) * 2018-07-23 2020-01-23 Translate Bio, Inc. Dry powder formulations for messenger rna

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
AU2017357758B2 (en) 2016-11-10 2023-11-16 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
AU2019376660B2 (en) 2018-11-09 2025-06-26 Translate Bio, Inc. 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities
EP4146680A1 (en) 2020-05-07 2023-03-15 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia
WO2021226468A1 (en) 2020-05-07 2021-11-11 Translate Bio, Inc. Improved compositions for cftr mrna therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125281A1 (en) * 2001-08-27 2003-07-03 David Lewis Compositions and processes using siRNA, amphipathic compounds and polycations
CN105813656A (zh) * 2013-10-22 2016-07-27 夏尔人类遗传性治疗公司 用于递送信使rna的脂质制剂
US20150376144A1 (en) * 2014-06-24 2015-12-31 Shire Human Genetic Therapies, Inc. Stereochemically enriched compositions for delivery of nucleic acids
CN107848988A (zh) * 2015-06-19 2018-03-27 麻省理工学院 烯基取代的2,5‑哌嗪二酮和其在组合物中用于向个体或细胞递送药剂的用途
CN110167922A (zh) * 2016-11-08 2019-08-23 特拉维夫大学拉莫特有限公司 用于核酸递送的阳离子脂质及其制备
US20200022921A1 (en) * 2018-07-23 2020-01-23 Translate Bio, Inc. Dry powder formulations for messenger rna

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RAFIQUE UL ISLAM ET AL: "Efficient nucleic acid transduction with lipoplexes containing novel piperazineand polyamine-conjugated cholesterol derivatives", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, no. 19, 6 November 2008 (2008-11-06), pages 100 - 103 *
SARA TRABULO ET AL: "A non-covalent strategy combining cationic lipids and CPPs to enhance the delivery of splice correcting oligonucleotides", 《JOURNAL OF CONTROLLED RELEASE》, vol. 145, 30 March 2010 (2010-03-30), pages 149 - 158, XP029820009, DOI: 10.1016/j.jconrel.2010.03.021 *
华雪莲等: "新型阳离子脂质体制备及应用研究", 《化学研究与应用》, vol. 31, no. 2, 28 February 2019 (2019-02-28), pages 177 - 183 *

Also Published As

Publication number Publication date
AU2021349262A1 (en) 2023-06-08
US20230357166A1 (en) 2023-11-09
KR20230074526A (ko) 2023-05-30
AU2021349262A9 (en) 2025-03-13
ES2994955T3 (en) 2025-02-04
JP7791182B2 (ja) 2025-12-23
MX2023003344A (es) 2023-06-05
EP4216933B1 (en) 2024-09-18
WO2022066916A1 (en) 2022-03-31
IL301536A (en) 2023-05-01
JP2023542944A (ja) 2023-10-12
EP4216933A1 (en) 2023-08-02
CA3193347A1 (en) 2022-03-31
EP4216933C0 (en) 2024-09-18
BR112023005207A2 (pt) 2023-04-25

Similar Documents

Publication Publication Date Title
CN116457027A (zh) 基于哌嗪的阳离子脂质
CN115667207B (zh) 基于酚酸脂质的阳离子脂质
WO2022221688A1 (en) "good"buffer-based cationic lipids
CN116507606B (zh) 基于tes的阳离子脂质
CN118922409A (zh) 非对称的基于哌嗪的阳离子脂质
CN121568920A (zh) 具有芳香族头基团的基于三(羟甲基)甲基甘氨酸和柠檬酸的阳离子脂质
CN121464146A (zh) 具有芳香族头基团的基于固醇的阳离子脂质
CN121752576A (zh) 用于核酸递送的辅助脂质
CN121285547A (zh) 基于“古德”缓冲液的阳离子脂质
KR20230171974A (ko) “good” 완충제-기반 양이온성 지질
HK40099554B (en) Piperazine-based cationic lipids
HK40099554A (en) Piperazine-based cationic lipids
CN117136182A (zh) 基于“古德”缓冲液的阳离子脂质

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination